Journal Home
Search for

Volume 27, Issue 4, Pages 265-275 (December 2004)

1 of 11 View next.

Treatment for substance use disorders in a privately insured population under managed care: Costs and services use

Shelly F. Greenfield, M.D., M.P.H.abCorresponding Author Informationemail address, Vanessa Azzone, Ph.D.c, Haiden Huskamp, Ph.D.c, Brian Cuffel, Ph.D.d, Thomas Croghan, M.D.e, William Goldman, M.D.d, Richard G. Frank, Ph.D.c

Received 10 October 2003; received in revised form 15 June 2004; accepted 9 July 2004.

Abstract 

The study investigated the relationship of substance use disorders, concurrent psychiatric disorders, and patient demographics to patterns of treatment use and spending in behavioral health and medical treatment sectors. We examined claims data for individuals covered by the same organization. Services spending and use were examined for 1899 individuals who received substance use disorder treatment in 1997. Medical and pharmacy spending was assessed for 590 individuals (31.1%). The most prevalent services were outpatient, intensive outpatient, residential, and detoxification. Average mental health/substance abuse (MHSA) care spending conditional on use was highest for those with concurrent alcohol and drug disorders ($5235) compared to those with alcohol ($2507) or drugs ($3360) alone; other psychiatric illness ($4463) compared to those without ($1837); and employees’ dependents ($4138) compared to employees ($2875) or their spouses ($2744). A significant minority also sought MHSA services in the medical sector. Understanding services use and associated costs can best be achieved by examining services use across treatment sectors.

a McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA

b Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA

c Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA

d United Behavioral Health, San Francisco, CA 94105, USA

e RAND Corporation, Arlington, VA 22202-5050, USA

Corresponding Author InformationCorresponding author. McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA. Tel.: +1 617 855 2241; fax: +1 617 855 2699

PII: S0740-5472(04)00086-8

doi:10.1016/j.jsat.2004.07.002

1 of 11 View next.